A Phase 1 interventional study of Alisertib in B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma and Diffuse Large B-cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-31.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States — 57 open to participants now, 95 under way, 6 of them phase 3. Lymphoma, B-Cell, Marginal Zone · United States.
Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, this one is the 163rd largest by enrollment of the 557 interventional ones that give a count, is one of 34 that started in 2008, is one of 247 in phase 1, and was the 360th registered.
875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →57 of the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Australia, France and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Canada and 9 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
674 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 325 · Phase 2 306 · Phase 3 45 · Phase 4 1
First in 1988; this study’s year is marked. 34 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 40 across 681 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 36 across the 557 interventional studies, 55 across the 33 observational. Of the 539 that completed or were terminated, 182 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 674 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 2 studies filed under Lymphoma, B-Cell, Marginal Zone — fewer than ten, so there is no comparison to draw.
25 of the studies in Lymphoma, B-Cell, Marginal Zone with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04799275Phase 3National Cancer Institute (NCI)Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | 2027-03-01 |
| NCT04212013Phase 3Memorial Sloan Kettering Cancer CenterA Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | 2027-03-18 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06860880UNC Lineberger Comprehensive Cancer CenterCombating Cancer-Related Fatigue: A Personalized Supportive Care Program | 2026-12-31 |
| NCT05700149International Extranodal Lymphoma Study Group (IELSG)Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | 2026-12-31 |
Add all 25 to your calendar (.ics) → With an account.
Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
The drug being tested in this study is called alisertib. Alisertib is being tested to treat people who have advanced hematological malignancies. This study determined the dose-limiting toxicity, maximum tolerated dose, safety and pharmacokinetics (how the drug moves through the body) for alisertib when given once or twice a day for 7 to 21 days.
This open label study enrolled 58 patients. Participants were enrolled in one of 3 treatment groups:
All participants received treatment for 12 months or until their disease progressed or they experienced unacceptable alisertib-related toxicity. This multi-center trial was conducted in the United States. The overall time to participate in this study was 422 days. Participants made multiple visits to the clinic, including a final visit 30 days after receiving their last dose of alisertib for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
disease and a or cytologically confirmed hematological of the following type for which standard curative treatment does not exist or is no longer effective:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
Drug: Alisertib
Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
Drug: Alisertib
Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
Drug: Alisertib
Alisertib (MLN8237) PIC or ECT
Also known as: MLN8237
Number of Participants With Dose-Limiting Toxicity (DLT)
DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib:1. Grade 4 neutropenia lasting ≥7 consecutive days, 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>21 days due to failure of adequate hematologic or non-hematologic recovery from previous cycle of treatment 8. Other alisertib related non-hematologic toxicities ≥Grade 2 that, in the opinion of the investigator required a dose reduction or discontinuation of therapy with alisertib.
Time frame: From first dose of study drug to 30 days after the last dose (up to 422 days)
Maximum Tolerated Dose (MTD) of Alisertib
MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.
Time frame: From first dose of study drug to 30 days after the last dose (up to 422 days)
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose
Terminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose
Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple time points (up to 6 hours) postdose
Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21
Time frame: Cycle 1 Day 21 predose and at multiple timepoints (up to 6 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Terminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14
Time frame: Cycle 1 Day 14 predose and at multiple timepoints (up to 8 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 12 hours) postdose
Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
Time frame: Cycle 1 Day 1 predose and at multiple timepoints (up to 12 hours) postdose
Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1
Time frame: Cycle 1 Days 1 predose and at multiple timepoints (up to 12 hours) postdose
AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Accumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7
Time frame: Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose
Best Overall Response Rate Based on Investigator's Assessment
Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions.
Time frame: Baseline and every 2 cycles up to Month 12 until disease progression, 30 days after end of treatment (up to 422 days)
Duration of Response (DOR)
DOR is defined as the time from the date of first documentation of a response (either CR or PR) to the date of first documentation of progressive disease (PD) according to International Working Group (IWG) criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
Time frame: Baseline and every 2 cycles up to Month 12 until disease progression, 30 days after end of treatment (up to 422 days)
Number of Participants With Polymorphisms in Gene Encoding Enzyme UGT1A1
One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype participants for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type. \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression. Not determined = blood sample was not evaluable.
Time frame: Cycle 1 Day 1 predose
Number of Participants With Polymorphisms in Aurora A Kinase
Time frame: Cycle 1 Day 1 predose
Participants took part in the study at 10 investigative sites in the United States from 11 July 2008 to19 October 2016.
| Milestone | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL |
|---|---|---|---|
| Started | 28 | 28 | 2 |
| Completed | 0 | 2 | 1 |
| Not completed | 28 | 26 | 1 |
| Withdrew: Adverse event | 4 | 5 | 0 |
| Withdrew: Progressive disease | 19 | 18 | 0 |
| Withdrew: Symptomatic deterioration | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 |
| Withdrew: Reason not specified | 3 | 0 | 1 |
DLT was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and was defined as any of the following events related to therapy with alisertib:1. Grade 4 neutropenia lasting ≥7 consecutive days, 2. Grade 4 neutropenia with fever and/or infection 3. Platelet count \<25,000/mm\^3 4. Grade 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis 5. Grade 3 or greater diarrhea despite maximal supportive therapy with loperamide 6. Any other Grade 3 or greater nonhematologic toxicity, with the following exceptions: Grade 3 arthralgia/myalgias, Any grade of alopecia, Brief (\<1 week) Grade 3 fatigue 7. Treatment delay of \>21 days due to failure of adequate hematologic or non-hematologic recovery from previous cycle of treatment 8. Other alisertib related non-hematologic toxicities ≥Grade 2 that, in the opinion of the investigator required a dose reduction or discontinuation of therapy with alisertib.
| participants | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D | Alisertib 90 mg PIC QD 14D | Alisertib 40 mg ECT QD 14D | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicity (DLT) | 1 | 2 | 0 | 1 | 2 | 2 | 2 | 0 | 0 | 1 |
MTD was defined as the highest dose at which DLT occurred in 0/3 or 1/6 participants.
| mg BID for 7 days | Alisertib |
|---|---|
| Maximum Tolerated Dose (MTD) of Alisertib | 50 |
| nM | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1 | 833.2 ± 49.5 | 1078.3 ± 26.4 |
| nM | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 1337.6 ± 57.8 | 1451.9 ± 26.2 |
| hours (h) | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1 | 2.0 (2.0 to 3.3) | 2.0 (1.1 to 5.2) |
| h | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 2.0 (1.0 to 5.0) | 2.0 (2.0 to 2.0) |
| nM*h | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 14846 ± 69.7 | 16528 ± 35.6 |
| h | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 20.5 ± 7.3 | 19.5 ± 6.0 |
| ratio | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 1.9 ± 1.1 | 1.5 ± 0.5 |
| ratio | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 6.0 ± 4.4 | 4.3 ± 1.5 |
| L/h | Alisertib 25mg PIC QD 21D | Alisertib 35 mg PIC QD 21D |
|---|---|---|
| CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 21 | 3.2 ± 113 | 4.1 ± 45 |
| nM | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D | Alisertib 90 mg PIC QD 14D |
|---|---|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1 | 726.5 ± 34.8 | 1637.0 ± 58.0 | 1773.4 ± 44.3 | 2497.4 ± 24.3 |
| nM | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D |
|---|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 2193.5 ± NA | 1634.4 ± 52.5 | 2300.2 ± 40.3 |
| h | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D | Alisertib 90 mg PIC QD 14D |
|---|---|---|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 1 | 2.0 ± 34.8 | 3.0 ± 58.0 | 2.0 ± 44.3 | 2.9 ± 24.3 |
| h | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D |
|---|---|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 3.4 ± NA | 2.0 ± 52.5 | 2.0 ± 40.3 |
| nM*h | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D |
|---|---|---|---|
| AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 23444 ± NA | 19671 ± 64.8 | 28864 ± 39.9 |
| ratio | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D |
|---|---|---|---|
| Accumulation Ratio (Rac) for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 2.4 ± 0.00 | 1.5 ± 0.5 | 1.9 ± 1.6 |
| ratio | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D |
|---|---|---|---|
| Peak/Trough Ratio for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 4.1 ± NA | 5.4 ± 1.9 | 4.4 ± 0.8 |
| L/h | Alisertib 35 mg PIC QD 14D | Alisertib 45 mg PIC QD 14D | Alisertib 65 mg PIC QD 14D |
|---|---|---|---|
| CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Pill in Capsule (PIC) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 2.9 ± NA | 4.3 ± 44 | 4.3 ± 53 |
| nM | Alisertib 40 mg ECT QD 14D |
|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1 | 1227 ± 41.3 |
| nM | Alisertib 40 mg ECT QD 14D |
|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 1608 ± NA |
| h | Alisertib 40 mg ECT QD 14D |
|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 1 | 3.9 ± NA |
| h | Alisertib 40 mg ECT QD 14D |
|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 5.0 ± NA |
| nM*h | Alisertib 40 mg ECT QD 14D |
|---|---|
| AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 14306 ± 20.3 |
| h | Alisertib 40 mg ECT QD 14D |
|---|---|
| Terminal Half Life for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 11.7 ± NA |
| ratio | Alisertib 40 mg ECT QD 14D |
|---|---|
| Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 2.1 ± NA |
| L/h | Alisertib 40 mg ECT QD 14D |
|---|---|
| CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Once Daily for 14 Days (QD14D) Dosing at Day 14 | 2.5 ± NA |
| nM | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1 | 886 ± 39.7 | 1114 ± 37.1 | 1531 ± 58.4 |
| nM | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 2025 ± 29.6 | 2586 ± 35.7 | 2058 ± 44.6 |
| h | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1 | 2.0 ± 39.7 | 2.2 ± 37.1 | 2.0 ± 58.4 |
| h | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 2.0 ± 39.7 | 2.2 ± 37.1 | 2.0 ± 58.4 |
| nM*hr | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 1 | 5518 ± 18.3 | 7095 ± 42.5 | 9732 ± 48.5 |
| nM*hr | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| AUCt: Area Under the Concentration Time Curve From Time 0 to Time t for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 16024 ± 20.3 | 18624 ± 27.3 | 17914 ± 48.6 |
| h | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 13.3 ± NA | 19.9 ± 10.7 | 18.4 ± 13.9 |
| ratio | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Accumulation Ratio (Rac) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 2.9 ± 0.5 | 2.8 ± 1.0 | 2.3 ± 0.9 |
| ratio | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| Peak/Trough Ratio for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 2.5 ± 0.6 | 2.4 ± 0.5 | 2.5 ± 2.2 |
| L/h | Alisertib 30 mg ECT BID 7D | Alisertib 40 mg ECT BID 7D | Alisertib 50 mg ECT BID 7D |
|---|---|---|---|
| CLss/F: Apparent Oral Clearance at Steady State for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7 | 3.7 ± 0.7 | 4.4 ± 1.9 | 6.7 ± 5.6 |
Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions.
| percentage of participants | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL |
|---|---|---|---|
| Best Overall Response Rate Based on Investigator's Assessment | 13 | 9 | 100 |
DOR is defined as the time from the date of first documentation of a response (either CR or PR) to the date of first documentation of progressive disease (PD) according to International Working Group (IWG) criteria. CR is defined as the disappearance of all evidence of disease and the definition for PR includes at least a 50% decrease in sum of the product of the diameters and no new lesions. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
| months | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL |
|---|---|---|---|
| Duration of Response (DOR) | 0.03 (0.03 to 3.65) | 2.07 (0.03 to 4.18) | 0.03 (0.03 to 0.03) |
One peripheral blood sample (approximately 4 mL) was to be obtained on Day 1 of Cycle 1 prior to the first dose of alisertib to genotype participants for polymorphisms in UGT1A1 because UGT1A1 is one of the enzymes responsible for glucuronidation of alisertib, which is expected to contribute to the clearance of alisertib. wt=wild type. \*28=polymorphism in the promoter region of a UGT1A1 allele resulting in reduced UGT1A1 expression. Not determined = blood sample was not evaluable.
| participants | Alisertib |
|---|---|
| wt/wt | 23 |
| wt/*28 | 23 |
| *28/*28 | 8 |
| other/other | 1 |
| Not Determined | 2 |
| Missing | 1 |
No measurements were reported for this outcome.
Collected over From first dose of study drug to 30 days after the last dose (up to 422 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 PIC Dose Escalation | — | 12/28 (42.9%) | 28/28 (100%) |
| Part 1 ECT Dose Escalation | — | 15/28 (53.6%) | 28/28 (100%) |
| Part 2 PTCL | — | 2/2 (100%) | 2/2 (100%) |
| Event | Part 1 PIC Dose Escalation | Part 1 ECT Dose Escalation | Part 2 PTCL |
|---|---|---|---|
| Staphylococcal bacteraemiaInfections and infestations | 0/28 | 0/28 | 1/2 |
| Herpes zosterInfections and infestations | 0/28 | 0/28 | 1/2 |
| DeliriumPsychiatric disorders | 0/28 | 0/28 | 1/2 |
| Lung infectionInfections and infestations | 0/28 | 0/28 | 1/2 |
| Abdominal painGastrointestinal disorders | 0/28 | 0/28 | 1/2 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/28 | 0/28 | 1/2 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/28 | 0/28 | 1/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/28 | 4/28 | 0/2 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/28 | 0/28 | 0/2 |
| Small intestinal obstructionGastrointestinal disorders | 0/28 | 2/28 | 0/2 |
| Event | Part 1 PIC Dose Escalation | Part 1 ECT Dose Escalation | Part 2 PTCL |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 13/28 | 18/28 | 2/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/28 | 13/28 | 2/2 |
| AnaemiaBlood and lymphatic system disorders | 11/28 | 12/28 | 2/2 |
| ConstipationGastrointestinal disorders | 2/28 | 5/28 | 2/2 |
| StomatitisGastrointestinal disorders | 3/28 | 2/28 | 2/2 |
| HypokalaemiaMetabolism and nutrition disorders | 3/28 | 7/28 | 2/2 |
| LeukocytosisBlood and lymphatic system disorders | 0/28 | 0/28 | 1/2 |
| SplenomegalyBlood and lymphatic system disorders | 0/28 | 0/28 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 9/28 | 14/28 | 1/2 |
| Dry mouthGastrointestinal disorders | 4/28 | 1/28 | 1/2 |
Safety population is defined as all participants who received any amount of alisertib.
| Age, Continuous(years) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| Mean | 61.4 ± 8.91 | 59.5 ± 14.22 | 63.0 ± 24.04 | 60.5 ± 12.03 |
| Sex: Female, Male(Participants) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| Female | 14 | 15 | 2 | 31 |
| Male | 14 | 13 | 0 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 7 | 0 | 16 |
| Not Hispanic or Latino | 19 | 20 | 2 | 41 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| White | 24 | 26 | 2 | 52 |
| Black or African American | 3 | 1 | 0 | 4 |
| Asian | 0 | 1 | 0 | 1 |
| Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| United States | 28 | 28 | 2 | 58 |
| Height(cm) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| Mean | 165.9 ± 11.25 | 164.6 ± 10.95 | 160.6 ± 6.43 | 165.1 ± 10.89 |
| Weight(kg) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| Mean | 81.40 ± 20.031 | 77.62 ± 19.747 | 97.65 ± 43.911 | 80.13 ± 20.573 |
| Body Surface Area(m^2) | Part 1: PIC Dose Escalation | Part 1: ECT Dose Escalation | Part 2: PTCL | Total |
|---|---|---|---|---|
| Mean | 1.93 ± 0.282 | 1.88 ± 0.289 | 2.05 ± 0.434 | 1.91 ± 0.286 |
Ran from Jul 2008 to primary completion in Oct 2016, 98 months.
Results were first posted in May 2019, 2 years 7 months after primary completion.
Of 81 phase 1 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 102. This study's 98 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Lymphoma, B-Cell, Marginal Zone →
Millennium Pharmaceuticals, Inc. →